Q1 2022 13F Holders as of 31 Mar 2022
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
10,912,791
-
Share change
-
-487,298
-
Total reported value
-
$116,191,000
-
Price per share
-
$11.10
-
Number of holders
-
26
-
Value change
-
-$3,240,025
-
Number of buys
-
14
-
Number of sells
-
27
Institutional Holders of MOONLAKE IMMUNOTHERAPEUTICS - COM (HLXA) as of Q1 2022
As of 31 Mar 2022,
MOONLAKE IMMUNOTHERAPEUTICS - COM (HLXA) was held by
26 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
10,912,791 shares.
The largest 10 holders included
Cormorant Asset Management, LP, FMR LLC, 683 Capital Management, LLC, BlackRock Inc., CITADEL ADVISORS LLC, STALEY CAPITAL ADVISERS INC, PRICE T ROWE ASSOCIATES INC /MD/, Beryl Capital Management LLC, Alpha Wave Global, LP, and Avidity Partners Management LP.
This page lists
26
institutional shareholders reporting positions in this security
for the Q1 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.